NCT03903211View on ClinicalTrials.gov

Longitudinal Changes of [18F]PI-2620 Positron Emission Tomography in Subjects With Cognitively Normal, Mild Cognitive Impairment and Alzheimer's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

April 9, 2019

Primary Completion Date

February 28, 2021

Study Completion Date

February 28, 2021

Conditions
Cognitively NormalMild Cognitive ImpairmentAlzheimer Disease
Interventions
DRUG

[18F]PI-2620

Imaging for evaluating the accumulation of abnormal tau protein in the brain

Trial Locations (1)

05505

Asan Medical Center, Seoul

All Listed Sponsors
lead

Jae Seung Kim

OTHER

NCT03903211 - Longitudinal Changes of [18F]PI-2620 Positron Emission Tomography in Subjects With Cognitively Normal, Mild Cognitive Impairment and Alzheimer's Disease | Biotech Hunter | Biotech Hunter